- Investing Ideas
- /
- Global High Growth Potential Companies
Global High Growth Potential Companies
Results
8701
0 new
Companies with a Future performance score of at least 3, ordered by Future performance score.
8,701 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
ANUP | ₹3,270.80 | -3.6% | 137.5% | ₹65.4b | ₹3,850.00 | PE54.6x | E21.5% | 0.2% | Capital Goods | ||
YGG | ฿0.54 | -18.2% | -92.7% | ฿325.1m | ฿10.75 | PS1.2x | E85.5% | 49.6% | Media | ||
ACI | ₹688.90 | 0.3% | 31.2% | ₹85.0b | ₹835.29 | PE38.7x | E43.0% | 0.4% | Materials | ||
DOMS | ₹2,710.05 | -2.8% | n/a | ₹164.5b | ₹3,030.29 | PE88.6x | E22.9% | 0.09% | Commercial Services | ||
505283 | ₹1,546.50 | -2.4% | 167.4% | ₹100.3b | ₹1,833.00 | PE52.9x | E26.3% | 0.4% | Capital Goods | ||
CONCORDBIO | ₹1,915.00 | 1.7% | 55.4% | ₹200.3b | ₹2,041.25 | PE61.1x | E26.9% | 0.5% | Pharmaceuticals & Biotech | ||
SFPTECH | RM 0.65 | -1.5% | -36.1% | RM 1.5b | RM 0.96 | PE38.3x | E24.5% | 0.6% | Capital Goods | ||
TVTX | US$17.39 | -8.6% | 202.4% | US$1.5b | US$27.00 | PS7.4x | E72.4% | n/a | Pharmaceuticals & Biotech | ||
CADLR | NOK 65.90 | -5.0% | 95.9% | NOK 23.1b | NOK 81.25 | PS16.1x | E68.0% | n/a | Capital Goods | ||
ZVRA | US$8.60 | -4.0% | 92.0% | US$460.1m | US$20.00 | PS18.7x | E73.4% | n/a | Pharmaceuticals & Biotech | ||
ONON | US$51.49 | -2.3% | 80.9% | US$16.6b | US$58.60 | PE116.2x | E29.7% | n/a | Consumer Durables | ||
MVW | NOK 9.85 | 1.5% | 44.9% | NOK 322.3m | NOK 12.20 | PS18.7x | E70.8% | n/a | Materials | ||
GAU | CA$2.03 | 4.6% | 144.6% | CA$516.4m | CA$3.51 | PS2.2x | E89.2% | n/a | Materials | ||
RHM | €582.40 | 3.1% | 108.9% | €25.3b | €642.07 | PE36.9x | E28.7% | 1.0% | Capital Goods | ||
AFISH | NOK 69.50 | -7.3% | -13.1% | NOK 2.2b | NOK 81.00 | PE68x | E94.4% | n/a | Food, Beverage & Tobacco | ||
TGTX | US$29.61 | -3.7% | 131.0% | US$4.2b | US$37.22 | PS16x | E56.5% | n/a | Pharmaceuticals & Biotech | ||
ARES | US$167.43 | -2.3% | 54.5% | US$52.3b | US$174.38 | PE78.2x | E46.3% | 2.2% | Diversified Financials | ||
NEWBRY | SEK 3.68 | -7.5% | 1.1% | SEK 89.3m | SEK 8.00 | PS2.4x | E130.0% | n/a | Pharmaceuticals & Biotech | ||
ACE | SEK 2.76 | 4.2% | -4.7% | SEK 265.2m | SEK 8.25 | PB2.5x | E47.2% | n/a | Pharmaceuticals & Biotech | ||
ELABS | NOK 10.12 | -5.4% | -42.2% | NOK 1.1b | NOK 22.00 | PS12.2x | E103.6% | n/a | Software | ||
ALKT | US$36.49 | -3.1% | 59.3% | US$3.6b | US$44.30 | PS11.6x | E98.6% | n/a | Software | ||
PHM | €73.45 | -9.0% | 95.9% | €1.3b | €84.60 | PE2071.1x | E56.4% | 0.9% | Pharmaceuticals & Biotech | ||
CCOLA | ₺49.10 | 7.9% | 30.2% | ₺137.4b | ₺85.53 | PE10.7x | E42.0% | 1.5% | Food, Beverage & Tobacco | ||
RMDA | ج.م3.50 | -4.4% | 127.4% | ج.م5.3b | ج.م4.23 | PE23.2x | E30.2% | 1.9% | Pharmaceuticals & Biotech |